Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Available 2Recruiting 1

Sponsor Class

INDUSTRY 5NIH 1

Study Type

Interventional 3Expanded_access 2

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1Other 1CNS 1

Conditions

Prostatic Neoplasms 1Prostate Cancer Recurrent 1Ototoxicity 1Neoplasm Metastasis 1Mucositis 1Glioblastoma 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × tempol × Clear all
NCT03480971 2024-11-20

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Matrix Biomed, Inc.

Phase 2 Recruiting
120 enrolled
Other

Ototoxicity, Mucositis

NCT05491928 2022-09-01

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Matrix Biomed, Inc.

Available
Tumor-Agnostic

Neoplasm Metastasis

NCT04876755 2021-05-06

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04337099 2021-05-05

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Matrix Biomed, Inc.

Available
Genitourinary

Prostatic Neoplasms

NCT04874506 2021-05-05

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡